A phase 2 study of ibrutinib as neoadjuvant therapy in patients with localized prostate cancer. Predicted probability of csPCa at biopsy.
CLEVELAND--(BUSINESS WIRE)--Cleveland Diagnostics, Inc., a pioneering, commercial-stage precision oncology company, announced today that the U.S. Food and Drug Administration (FDA) has approved the ...
CLEVELAND--(BUSINESS WIRE)--Cleveland Diagnostics, Inc., a commercial-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, announced today the ...
A new blood test called IsoPSA has been developed by researchers, that helps in detecting prostate cancer and reduces the rate of biopsies by almost 50 percent. IsoPSA, a new blood test detects ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results